Infliximab in hidradenitis suppurativa: A systematic review and meta‐analysis

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory often recalcitrant to treatment. There is a lack of an updated systematic data review for infliximab use in HS. We conducted a systematic review and meta-analysis of literature on infliximab in HS. This study was performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and was pre-registered on PROSPERO (CRD42021283596). In 9/2021, MEDLINE and EMBASE were systematically searched for articles on infliximab in HS. Non-English, duplicate, and studies with <5 HS patients were excluded. Study quality was assessed utilizing Cochrane Risk of

S2k-Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa (ICD-10-Code: L73.2)

“…Infliximab ist ein bei HS/AI wirksames, nicht zugelassenes Arzneimittel 232 396 . Es ist ein chimärer (Maus/Mensch) monoklonaler Antikörper gegen TNF-α.…”

“…Außerdem wurde in Woche 8 ein signifikanter Rückgang der Entzündungsmarker beobachtet. In einer Metaanalyse mit 314 Patienten mit mittelschwerer bis schwerer HS/AI konnte eine Ansprechrate von 83 % gezeigt werden 396 .…”

“…Bei Patienten mit partiellem Ansprechen oder Reduktion des Ansprechens auf Adalimumab mit der Zeit kann eine kurzfristige Therapieintensivierung (80 mg/Woche s. c. über mindestens einen Monat) zu signifikanter Wirkungszunahme führen [394,395]. [396].…”

Current Medical and Surgical Treatment of Hidradenitis Suppurativa—A Comprehensive Review

“…Infliximab is a chimeric mouse/human IgG1 monoclonal antibody with high affinity to soluble and transmembrane bound TNF⍺. A recent metanalysis calculated a pooled response rate for infliximab of 83% in patients with moderate-to-severe HS and described a low toxicity with a rate of 2.9% for severe adverse events [ 130 ]. In a phase II placebo-controlled crossover study, 57% of patients under infliximab treatment reached a reduction of the HS Severity index (HSSI) of >50% compared to 5% in the placebo group.…”

“…In another prospective trial, sustained treatment responses were observed in HS patients after a single course of infliximab [ 132 ]. Overall, infliximab is a promising treatment option for HS; however, larger prospective randomized trials are needed to investigate its efficacy compared to other biologic therapies [ 130 ].…”